Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Dermatologic 2Plasma cell 1Gynecologic 1Breast 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 36Melphalan 29Cyclophosphamide 28Specimen Handling 26Biopsy 26Bortezomib 24Calcium Dobesilate 20Magnetic Resonance Spectroscopy 19Lenalidomide 17fludarabine phosphate 15Filgrastim 15Peripheral Blood Stem Cell Transplantation 13Vincristine 12Prednisone 12dexamethasone acetate 11dexamethasone 21-phosphate 11auricularum 11carfilzomib 10Doxorubicin 10sargramostim 9fludarabine 8Thalidomide 8Interferon-alpha 7Cyclosporine 7Busulfan 7trametinib 6ixazomib 6Rituximab 6Etoposide 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × GSK2141795 × Plasma cell × Clear all
NCT01989598 2022-03-02

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
25 enrolled 11 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡